Glycomimetic Compounds Inhibit Pathogen-Host Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating influenza are inadequate, particularly in the context of pandemic outbreaks, where there is a significant lag in vaccine production and existing treatments are not effective against rapidly mutating viruses.
Innovation Solution
Development of glycomimetic compounds that inhibit the binding of pathogens to cell surface sialylated galactose, specifically designed to mimic natural glycan receptors to block virus adherence and infection, including compounds of Type I, Type II, Type III, Type IV, and Type V formulas with various functional groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccine production methods are used to prevent influenza, then immunity protection is provided, but there is a significant lag time of approximately 6 months from virus identification to vaccine availability
Solution Approach 1:
The patent develops glycomimetic compounds that mimic sialylated galactose receptors in advance, creating pre-formed inhibitors that can immediately block pathogen binding. These compounds are designed beforehand to recognize and bind to conserved regions of viral hemagglutinin, so when a pandemic strain emerges, the inhibitors are already available or can be rapidly deployed without waiting for strain-specific vaccine production
Solution Approach 2:
The glycomimetic compounds serve as intermediary molecules that compete with host cell receptors for binding to viral hemagglutinin. These synthetic sugar mimics act as decoy receptors, binding to the virus and preventing actual infection while being chemically synthesizable and modifiable for rapid deployment against different strains
2Object-affected harmful factors
If existing antiviral treatments are used, then some symptom relief is provided, but they are not effective against rapidly mutating viruses and have limited broad-spectrum protection
Solution Approach 1:
The glycomimetic compounds are designed to target conserved regions of viral hemagglutinin that are essential for receptor binding but remain relatively unchanged across different influenza strains. By focusing on these invariant functional regions rather than variable surface epitopes, a single glycomimetic structure can provide protection against multiple strains including pandemic threats
Solution Approach 2:
The patent employs structure-activity relationship analysis to optimize the glycomimetic molecular parameters, including sugar ring configuration, substituent positions, and functional group arrangements. By systematically varying these chemical parameters, the compounds achieve high binding affinity for conserved viral regions while maintaining selectivity and resistance to viral mutation
3Object-affected harmful factors
If glycomimetic compounds are designed to mimic natural glycan receptors, then pathogen binding is blocked, but the molecular complexity and structural diversity of possible compounds increases
Solution Approach 1:
The glycomimetic compounds focus their molecular complexity specifically at the binding interface with viral hemagglutinin, where precise stereochemical recognition is needed. The core sugar mimic structure replicates the critical hydroxyl group arrangement for hydrogen bonding, while other portions of the molecule can be simplified or modified to improve pharmacological properties without compromising binding affinity
Data Source
AI summary
The present invention relates to novel glycomimetic compounds that are rationally designed to inhibit the binding of various pathogens to cell surface sialylated galactose and methods of use thereof. Specifically sialic acid glycosides and C-glycosides are disclosed that form a lactam ring structure or a cyclic ether/amine ring structure with the adjacent monosaccharide residue.